| |
In-hospital at day 90
|
All survivors*
|
|---|
|
Attribute
|
Placebo (mean ± SD)
|
AT III (mean ± SD)
|
P
†
|
Placebo (mean ± SD) AT III (mean ± SD)
| |
P
†
|
|---|
|
Mobility (%)
|
33 ± 26
|
38 ± 28
|
>0.1
|
49 ± 24
|
51 ± 24
|
>0.1
|
|
Physical activity (%)
|
33 ± 27
|
39 ± 26
|
>0.1
|
48 ± 23
|
50 ± 23
|
>0.1
|
|
Communication/speech (%)
|
42 ± 42
|
61 ± 35
|
0.01
|
52 ± 34
|
57 ± 32
|
0.03
|
|
Level of alertness (%)
|
41 ± 39
|
59 ± 33
|
0.02
|
51 ± 32
|
56 ± 31
|
0.02
|
|
Energy level (%)
|
34 ± 27
|
43 ± 26
|
0.09
|
47 ± 23
|
51 ± 22
|
0.02
|
|
Overall QoL (%)
|
35 ± 28
|
44 ± 27
|
>0.1
|
51 ± 23
|
53 ± 23
|
>0.1
|
|
Karnofsky scale (%)
|
22 ± 19
|
31 ± 19
|
0.03
|
45 ± 19
|
47 ± 19
|
>0.1
|
- Scores range from 0 to 100, and changes may range from -100 to +100. Higher scores represent better quality of life (QoL) and increases (i.e. positive changes) represent improvement. *90-day values calculated by last observation carried forward analysis (see text). †Nominal P value for two-sided, two-sample Wilcoxon test for differences between changes from baseline to 90-day QoL. AT, antithrombin.
